|
1.Marsha A. M.; Brem H.; Langer R. Advancing the field of drug delivery : taking aim at cancer. Cancer Cell. 2003, 4, 337-341.
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell. 2000,
100, 57-70.
3.Patterson D. M.; Rustin G. J. S. Vascular damaging agents. Clinical
Oncology 2007, 19, 443-456.
4. Wani, M. C.; Taylar, H. L.; Monroe E. Wall; Coggon, P.; McPhail A. T. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus breoifolia. J.
Am. Chem. Soc. 1971, 93, 2325-2327.
5.Johnson I. S.; Armstrong J. G.; Gorman, M.; Burnett, J. P. The vinca alkaloids : a new class of oncolytic agents. Cancer Res. 1967, 23, 1390-1427.
6.Shapiro G. I.; Harper J. W. Anticancer drug targets: cell cycle and
checkpoint control. The Journal of Clinical Investigation. 1999, 104, 1645-1653.
7.Murray A. W. Recycling the cell cycle: cyclins revisited. Cell. 2004,
116, 221-234.
8.Li L.; Wang H. K.; Kuo S. C.; Wu T. S.; Mauger A.; Link C. M.;
Hame L.; Lee K. H. Antitumor Agents 155. Synthesis and biological
evaluation of 3’,6,7-substituted 2-phenyl-4-quinolones as
antimicrotubule agents. J. Med. Chem. 1994, 37, 3400-3407.
9.Jiang J. B.; Hesson D. P.; Dusak B. A.; Dexter D. L.; Kang G. J.;
Hemel E. Synthesis and biological evaluation of 2-styrylquinazolin-
4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. J. Med. Chem. 1990, 33, 1721-1728.
10. 99年 01月 張峯碩論文
11.Jiang J. B.; Hesson D. P.; Dusak B. A.; Dexter D. L.; Kang G. J.;
Hamel E. Synthesis and biological evaluation of 2-styrylquinazolin-
4(3H)-ones, a new class of antimitotic anticancer agents which
inhibit tubulin polymerization. J. Med. Chem. 1990, 33, 1721-1728.
12.Hour M. J.; Huang L. J.; Kuo S. J.; Xia Y.; Bastow K.; Nakanishi Y.; Hamel E.; Hsiung L. K. 6-Alkylamino- and 2,3-dihydro-3’-methoxy-2- phenyl-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 2000, 43, 4479-4487.
13.Chang F. S.; Chen W. C.; Wang C. H.; Tzeng C. C.; Chen Y. L.
Synthesis and antiproliferative evaluations of certain 2-phenylvinyl
quinoline (2-styrylquinoline) and 2-furanylvinylquinoline
derivatives. Bioorg. & Med. Chem. 2010, 18, 124–133.
14.100 年 12 月 陳郁旻論文
15.Chen Y. W.,; Chen Y. L.,; Tseng C. H.,; Liang C.C.,; Yang C.N.,;
Yao Y. C.,; Lu P. J.,; Tzeng C.C. Discovery of 4-anilinofuro[2,3-b]
quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. J. Med. Chem. 2011, 54, 4446-4461.
16.100 年 06 月 駱柏誠論文
17.Cerri A.; Almirante N.; Barassi P.; Benicchio A.; Fedrizzi G.; Ferrari
P.; Micheletti R.; Quadri L.; Ragg E.; Rossi R.; Santagostino M.;
Schiavone A.; Serra F.; Zappavigna M. P.; Mellomi P.
17-O-aminoalkyloximes of 5-androstane-3, 14-diol withdigitalis-like
activity: synthesis, cardiotonic activity, structure-activity
relationships, and molecular modeling of the Na+, K+-ATPase
receptor. J. Med. Chem. 2000, 43, 2332-2349.
18.Okano M.; Mito J.; Maruyama Y.; Masuda H.; Niwa T.; Nakagawa
S.; Nakamura Y.; Matsuura A. Discovery and structure–activity
relationships of 4-aminoquinazoline derivatives, a novel class of
opioid receptor like-1 (ORL1) antagonists. Bioorg. & Med. Chem.
2009, 17, 119–132.
19.Mouscadet J. F.; Desmae D.; Subra F. Leh H.; Savoure D.; Auclair
C.; Angelo J. Styrylquinoline derivatives: a new class of potent
HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J. Med. Chem. 1998, 41, 2846-2857.
20.Sirisoma N.; Pervin A.; Zhang H.; Jiang S.; Willardsen A. J.;
Anderson B.M.; Mather G.; Pleiman M. C.; Kasibhatla S.; Tseng B.;
Drewe J.; Cai X.S. Discovery of N-(4-methoxyphenyl)-
N,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and
efficacious anticancer agent with high blood brain barrier
penetration. J. Med. Chem. 2009, 52, 2341–2351.
21.Silverstein, R. M.; Webster, F. X. 13C NMR Spectrometry. In
Spectrometric Identification of Organic Compounds, 6th ed.; Rose, N.,
Ed.; John Wiley and Sons. New York, 1998; pp 217-24.
|